GlassScriptPhysician profile
Michele A Hull
NPI 1235772112
$4,294.07
in general payments reported to CMS, 2019-2025
19 companies · $2,089 in 2025
The $2,089 reported for 2025 was more than what 93% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $172 · 2022: $374 · 2023: $789 · 2024: $870 · 2025: $2,089.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,748.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,747.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $1,047.08 | 2021-2025 | Aristada, Lybalvi, Vivitrol |
| Otsuka America Pharmaceutical, INC. | $554.66 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Teva Pharmaceuticals USA, INC. | $535.32 | 2022-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Neurocrine Biosciences, INC. | $467.54 | 2021-2025 | Ingrezza |
| Janssen Pharmaceuticals, INC | $363.10 | 2021-2025 | Invega Sustenna, Spravato |
| Vanda Pharmaceuticals INC. | $325.54 | 2022-2025 | Fanapt, Hetlioz |
| Abbvie INC. | $220.93 | 2021-2025 | |
| Lundbeck LLC | $215.54 | 2022-2025 | Rexulti, Abilify Asimtufii |
| Luye Pharma (USA) LTD. | $111.29 | 2025 | Erzofri Extended-Release |
| E.R. Squibb & Sons, L.L.C. | $107.24 | 2024-2025 | Cobenfy |
| Almatica Pharma LLC | $75.98 | 2023-2025 | Loreev Xr, Sertraline Hcl |
| Indivior INC. | $58.73 | 2023-2025 | Sublocade |
| Takeda Pharmaceuticals U.S.A., INC. | $43.80 | 2023-2024 | Trintellix |
| Ironshore Pharmaceuticals INC. | $41.50 | 2024 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $40.16 | 2025 | Caplyta |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $36.87 | 2022-2025 | Azstarys |
| Axsome Therapeutics, INC. | $17.47 | 2025 | Auvelity |
| Idorsia Pharmaceuticals US INC | $16.45 | 2023 | Quviviq |
| Braeburn INC. | $14.87 | 2023 | Brixadi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michele Hull listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.